Gongwin Biopharm Holdings Co (ROCO:6617) ROCE % : -3.17% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Gongwin Biopharm Holdings Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gongwin Biopharm Holdings Co's annualized ROCE % for the quarter that ended in Dec. 2024 was -3.17%.

Gongwin Biopharm Holdings Co ROCE % Historical Data

The historical data trend for Gongwin Biopharm Holdings Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gongwin Biopharm Holdings Co ROCE % Chart

Gongwin Biopharm Holdings Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-10.54

-10.49

-23.61

-6.67

-3.82

Gongwin Biopharm Holdings Co Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-9.67	-7.42	-4.27	-1.22	-3.17

Gongwin Biopharm Holdings Co ROCE % Calculation

Gongwin Biopharm Holdings Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-87.554	/	( ( (1515.348 - 126.359)	+	(3382.186 - 182.16) )	/ 2 )
	=	-87.554	/	( (1388.989	+	3200.026)	/ 2 )
	=	-87.554	/	2294.5075
	=	-3.82 %

Gongwin Biopharm Holdings Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-102.948	/	( ( (3453.699 - 163.33)	+	(3382.186 - 182.16) )	/ 2 )
	=	-102.948	/	( ( 3290.369	+	3200.026 )	/ 2 )
	=	-102.948	/	3245.1975
	=	-3.17 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Gongwin Biopharm Holdings Co (ROCO:6617) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gongwin Biopharm Holdings Co ROCE % Related Terms

Thank you for viewing the detailed overview of Gongwin Biopharm Holdings Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gongwin Biopharm Holdings Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gongwin Biopharm Holdings Co Ltd (ROCO:6617) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491

Website

http://www.gongwinbiopharm.com

Gongwin Biopharm Holdings Co Ltd is a Taiwanese biotech and pharmaceutical company engaged in research and development of anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma.

Gongwin Biopharm Holdings Co Headlines

No Headlines